Difference between revisions of "Template:Team:TU Eindhoven/Practices HTML"

(Created page with "<html> <div id="containercontent"> <br /> <br /> <br /> <br /> <h1> Policy practices </h1> </html>")
 
Line 9: Line 9:
 
Policy practices
 
Policy practices
 
</h1>
 
</h1>
 +
<br />
 +
<br />
 +
<h2>
 +
General Outline
 +
</h2>
 +
<br />
 +
<br />
 +
<span class="tekst1">
 +
To evaluate the utility of the E.coli sensor three different scenarios will be scrutinized. The E.coli sensor system could possibly be used for the detection of diseases related to disturbances in the intestinal tract. Furthermore we will examine the use of our sensor system to detect pathogens related to Q-fever, a societal problem in the Netherlands. Finally we will look at the applicability of the sensor system to reduce the use of pesticides.
 +
<br />
 +
<br />
 +
For each of these scenarios we have looked at law and legislation, ethical aspects and the vision of different stakeholders upon the problem and our proposed solution.
 +
<br />
 +
 +
Law and legislation is a critical factor when it comes to bringing a product to the market. Different instances are concerned with testing the safety of a product before it reaches the consumer. One of the important instances in the Netherlands that we contacted was the RIVM. In Europe the EMA is an important regulator, responsible for the scientific evaluation of medicines developed by pharmaceutical companies.
 +
<br />
 +
 +
Ethical aspects play an important role in the general attitude of the population towards new technological ideas and developments. Because we are using GMOs (Genetically Modified Organisms) in our application, this is an important part to take into account during our project. To introduce these new possibilities within the field of synthetic biology to society, we are giving presentations and have ethical debates with them about the risks, consequences and possibilities. For the ethical aspects around our applications we contacted the CCMO, an institute in the Netherlands that is responsible for performing ethical test on developed medical treatments. 
 +
<br />
 +
Other stakeholders we contacted are research institutes with regards to the intestinal tract, Q-fever and pesticides. Gastroenterologists and patients have been approached for the scenario about diseases within the intestinal tract. For the scenario about Q-fever we contacted infected farms and for the scenario about pesticides we contacted nurseries who are dealing with the overuse of pesticides.
 +
 +
</span>
 
</html>
 
</html>

Revision as of 13:04, 24 July 2015





Policy practices



General Outline



To evaluate the utility of the E.coli sensor three different scenarios will be scrutinized. The E.coli sensor system could possibly be used for the detection of diseases related to disturbances in the intestinal tract. Furthermore we will examine the use of our sensor system to detect pathogens related to Q-fever, a societal problem in the Netherlands. Finally we will look at the applicability of the sensor system to reduce the use of pesticides.

For each of these scenarios we have looked at law and legislation, ethical aspects and the vision of different stakeholders upon the problem and our proposed solution.
Law and legislation is a critical factor when it comes to bringing a product to the market. Different instances are concerned with testing the safety of a product before it reaches the consumer. One of the important instances in the Netherlands that we contacted was the RIVM. In Europe the EMA is an important regulator, responsible for the scientific evaluation of medicines developed by pharmaceutical companies.
Ethical aspects play an important role in the general attitude of the population towards new technological ideas and developments. Because we are using GMOs (Genetically Modified Organisms) in our application, this is an important part to take into account during our project. To introduce these new possibilities within the field of synthetic biology to society, we are giving presentations and have ethical debates with them about the risks, consequences and possibilities. For the ethical aspects around our applications we contacted the CCMO, an institute in the Netherlands that is responsible for performing ethical test on developed medical treatments.
Other stakeholders we contacted are research institutes with regards to the intestinal tract, Q-fever and pesticides. Gastroenterologists and patients have been approached for the scenario about diseases within the intestinal tract. For the scenario about Q-fever we contacted infected farms and for the scenario about pesticides we contacted nurseries who are dealing with the overuse of pesticides.